Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Management

Show all
Joseph W. Turgeon
President and Chief Executive Officer
Joseph

Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had recently served as Spectrum’s President and Chief Operating Officer from April 2014 to December 2017, and had previously served as the Company’s Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales. At Amgen he built and led the sales organization across multiple areas, including oncology, inflammation and bone health. Mr. Turgeon was responsible for launching most of the drugs and their dramatic growth at Amgen. He brings depth of experience in the oncology marketplace.

Mr. Turgeon holds a B.S. from Jacksonville University where he studied microbiology and economics.

Thomas J. Riga
Chief Operating Officer
Riga

Mr. Riga brings over 20 years of pharmaceutical sales and management experience in various positions at Wyeth Ayerst, Eli Lilly, Amgen and Dendreon. His experience spans sales, Six Sigma, marketing, manufacturing, and corporate accounts.

He had recently served as Spectrum’s Executive Vice President , Chief Commercial Officer and Head of Business Development from June 2017 to December 2017, and previously served as Spectrum’s Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.

Mr. Riga holds a B.S. from St. Lawrence University where he studied Biology and Chemistry.

Kurt A. Gustafson
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Gustafson

Mr. Gustafson has more than 20 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations.

Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he managed several successful financings and established a three year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years most recently as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as CFO of Amgen International and resided in Zug, Switzerland.

Mr. Gustafson holds a Bachelors of Arts degree in Accounting from North Park University in Chicago and a Masters in Business Administration from University of California, Los Angeles.

Keith M. McGahan LL.M, J.D., CCEP
Senior Vice President, Chief Legal Officer
Keith McGahan
Mr. McGahan joined Spectrum as the VP, Chief Compliance Officer and Assistant General Counsel in 2016 and was appointed SVP, Chief Legal Officer in 2018. Mr. McGahan brings over 20 years of compliance experience with over 16 years’ building corporate compliance programs. Prior to joining Spectrum, Mr. McGahan was a Navy Judge Advocate General (JAG). He served as the Assistant Staff Judge Advocate to the Navy Surgeon General, Chief Bureau Medicine and Surgery, Staff Judge Advocate to Naval Medical Research Command and Staff Judge Advocate to Naval Hospital Camp Pendleton. After leaving the Navy Mr. McGahan joined Johnson & Johnson as a Director of Healthcare Compliance and later as an Executive Director, Associate General Counsel at Avanir (Otsuka Pharmaceutical).
Zane Yang, MD
Senior Vice President, Clinical Development
Yang
Dr. Yang joins Spectrum from Inovio Pharmaceuticals where he was Vice President, Clinical Development Oncology for Inovio's entire Oncology Therapeutic Area. He led Inovio's Clinical Development for all oncology immunotherapies and cancer vaccines, as well as all collaborative activities with external organizations.  Prior to Inovio, he was Director of Medical Affairs and Clinical Development at Janssen, Novartis Oncology and Merck & Co.
 
Dr. Yang, who earned his M.D. at Beijing Medical University, was a fellow at Emory University's Winship Cancer Institute, University of Pennsylvania and the Wistar Institute in Philadelphia. Before transitioning to the pharmaceutical industry, he was associate professor at the University of Virginia Medical Center in Charlottesville, VA.
Michael A. Grabow
Senior Vice President, Corporate Strategy & Operations
Michael Grabow

Michael Grabow is responsible for leading Spectrum’s Corporate Strategy & Operations function. This function is accountable to coordinate, operationalize, and align the organization on the core strengths needed for Spectrum to be successful in the future. Michael is responsible for driving Corporate Strategy and Operational Excellence throughout the organization and is also responsible for Spectrum’s Commercial Operations, Marketing, and National Accounts functions.

Michael has over 23 years of operations, commercial and finance related experience in multiple industries with 18 of these years being within the pharmaceutical industry. Since joining Spectrum in 2013, Michael has held roles with increasing levels of responsibility within the Commercial Organization. In addition, Michael was recently named 2017 Executive of the Year.

Michael holds a Bachelor of Science degree in Finance from California State University, Northridge and a Masters in Business Administration from Pepperdine University.

Guru Reddy, PhD
Vice President, Preclinical Research & Development
Guru Reddy

Dr. Reddy has over 20 years of research and development management experience in the biotechnology industry and has a demonstrated track record of oncology drug development. He has diverse experience in preclinical research and development, early clinical development, regulatory strategy and IP strategy. He joined Spectrum in 2004 has taken increasing roles of responsibility. He is currently responsible for preclinical research and development and clinical pharmacology. At Spectrum, he has been part of four NDA submissions and three FDA approved products (FUSILEV, BELEODAQ and EVOMELA).

Prior to joining Spectrum, Dr. Reddy worked at Ciphergen Biosystems and Pangene Corporation. He was the scientific co-founder of Pangene Corporation and in charge of the oncology division of Pangene.

Dr. Reddy obtained his PhD in biochemistry from Poona University in India and post-doctoral training at Yale University. Dr. Reddy has published over 30 publications in peer reviewed journals and over 50 abstracts at international conferences. In addition, he is an inventor on 17 issued U.S. patents.

Shiv Kapoor
Vice President, Strategic Planning and Investor Relations
Shiv Kapoor

Mr. Kapoor has more than 20 years of experience in finance, investments, research, and regulatory primarily in the Biotechnology sector. Prior to joining Spectrum, he had a Wall Street career both as a Sell Side analyst at various investment banks, most recently as a Managing Director at Morgan Joseph, and as an investor, most recently as a Portfolio Manager at Citigroup. Previously, Mr. Kapoor held research, business development and regulatory roles at Johnson & Johnson, Guidant, and Alza Corporation. He also has been an early stage investor in several startups including LegalZoom, Infinera Corp, and Dilithium technologies.

Mr. Kapoor holds a B.A. in Molecular Cell Biology from University of California, Berkeley and an MBA focused in Strategy, Finance and Entrepreneurship where he studied microbiology and economics.

Lisa A. Croissant
Vice President, Sales
Bimal R. Shah
Vice President, Corporate and Business Development

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.